Form 4: Travere Therapeutics CFO Reports Stock Transactions Following PSU Vesting
SEC Form 4
Christopher R. Cline, CFO of Travere Therapeutics, reports the vesting of performance-based restricted stock units (PSUs) and subsequent sale of shares to cover tax obligations.
Summary
- On May 2, 2025, Christopher R. Cline, the CFO of Travere Therapeutics, had 4,920 performance-based restricted stock units (PSUs) vest.
- This vesting occurred because a performance criterion related to cumulative FILSPARI net revenue was achieved, as confirmed by the Issuer following the release of its financial results for the quarter ended March 31, 2025.
- Following the vesting, Cline sold 1,784 shares of common stock on May 5, 2025, at a price of $21.05 per share.
- This sale was mandated by Travere Therapeutics to cover the tax withholding obligation associated with the PSU settlement.
- After these transactions, Cline directly owns 93,126 shares of Travere Therapeutics common stock and 4,920 performance-based restricted stock units.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as the vesting of PSUs indicates the achievement of a performance target related to FILSPARI revenue. However, the subsequent sale of shares to cover taxes is a neutral event.
Positives
- The vesting of PSUs indicates that a performance criterion related to cumulative FILSPARI net revenue was achieved, suggesting positive performance for the company.
Future Outlook
NA
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives. The vesting of PSUs tied to FILSPARI revenue suggests confidence in the product's market performance.
Stakeholder Impact
- Shareholders may view the PSU vesting as a positive sign, indicating that the company is meeting its performance goals.
- The sale of shares to cover tax obligations has a minimal impact on stakeholders.
Key Dates
| Date | Description |
|---|---|
| 2022-09-01 | Reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock. |
| 2025-03-31 | Quarter ended for which financial results were released, confirming achievement of performance criterion. |
| 2025-05-02 | 4,920 PSUs vested due to achievement of performance criteria. |
| 2025-05-05 | 1,784 shares of common stock were sold at $21.05 per share to cover tax obligations. |
Keywords
Travere Therapeutics, TVTX, Christopher R. Cline, CFO, Form 4, PSU, Performance-based Restricted Stock Units, FILSPARI, Vesting, Stock Sale, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.